citalopram has been researched along with Disorders of Excessive Somnolence in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some residual symptoms, including restlessness, insomnia, and weight change, may help better identify patients with MDD vulnerable to relapse." | 1.46 | Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. ( Mimura, M; Sakurai, H; Suzuki, T; Uchida, H; Yoshimura, K, 2017) |
| "Fatigue is a common symptom in individuals with multiple sclerosis (MS)." | 1.39 | Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013) |
| "The manifestations of daytime somnolence and abnormal sleep behavior have been described in SCA type 3 (SCA3) and SCA type 6 (SCA6), but as yet have not been described in SCA type 1 (SCA1)." | 1.36 | Excessive daytime somnolence in spinocerebellar ataxia type 1. ( Cunnington, D; Dang, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakurai, H | 1 |
| Suzuki, T | 1 |
| Yoshimura, K | 1 |
| Mimura, M | 1 |
| Uchida, H | 1 |
| Dang, D | 1 |
| Cunnington, D | 1 |
| Pardini, M | 1 |
| Capello, E | 1 |
| Krueger, F | 1 |
| Mancardi, G | 1 |
| Uccelli, A | 1 |
3 other studies available for citalopram and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Disorders of Excessive Somnole | 2017 |
Excessive daytime somnolence in spinocerebellar ataxia type 1.
Topics: Activities of Daily Living; Amantadine; Ataxin-1; Ataxins; Brain Stem; Cerebellum; Citalopram; Dextr | 2010 |
Reward responsiveness and fatigue in multiple sclerosis.
Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso | 2013 |